A new treatment for a deadly form of brain cancer will get its date before an FDA panel this week, as NovoCure, a privately-held Israeli company, brings its NovoTTF-100A device before the agency’s neurological devices panel March 17.
The NovoTTF is described by the company as a “non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box,” according to product literature on the firm’s website.
The electrodes are worn on the outside of a shaved head and look like bandages with wires attached. The electrodes are then attached to the portable generator, which continuously pumps low-intensity, alternating electric fields directly onto the tumor site.
The FDA is considering the device as a treatment for glioblastoma “after surgical and radiation options have been exhausted,” according to a note in the federal public register. Glioblastoma is the most common form of brain tumor and has a low survival rate.
NovoCure was founded in 2000 by Yoram Palti, a physician at the Technion – Israel Institute of Technology. The company has been conducting a Phase III clinical trial of the device since June 2009. That trial is expected to be completed in October 2012. The FDA will be releasing more details on the device as the panel meeting approaches.
NovoCure counts New York-based venture capital firm WFD Ventures as a primary investor in the company.